Patent ID: 9593152
Date: 2017-03-14
CPC Classifications: A61K,A61P,C07K,C12N,C12P,G01N

Claim:
1. A method for treating disease, wherein said disease comprises cancer or human immunodeficiency virus (HIV), in a patient, the method comprising: a) administering to the patient a soluble fusion protein complex comprising at least two soluble fusion proteins, wherein the first fusion protein comprises (a) a first single chain T-cell receptor (scTCR) covalently linked to (b) interleukin-15 (IL-15) polypeptide; and the second fusion protein comprises (c) a second scTCR covalently linked to (d) soluble interleukin-15 receptor alpha (IL-15Ra) polypeptide; wherein the IL-15 polypeptide of the first fusion protein binds to the soluble IL-15Ra polypeptide of the second fusion protein to form a soluble fusion protein complex, and wherein the first scTCR and the second scTCR comprise a TCR V-α chain covalently linked to a TCR V-β chain by a peptide linker sequence; b) forming a specific binding complex (bridge) between antigen-expressing diseased cells and IL-15R-expressing immune cells sufficient to localize the immune cells; and c) damaging or killing the disease cells sufficient to prevent or treat the disease in the patient.